Eli Lilly to Acquire Kelonia Therapeutics for Up to $7 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 20 2026
0mins
Source: Yahoo Finance
- Acquisition Agreement Details: Eli Lilly has entered into a definitive agreement to acquire Kelonia Therapeutics for up to $7 billion, with $3.25 billion payable upfront and the remainder contingent on clinical, regulatory, and commercial milestones, indicating Lilly's strategic intent to expand in oncology.
- Optimistic Clinical Outlook: Kelonia's lead program, KLN-1010, is a Phase 1 investigational therapy for relapsed and refractory multiple myeloma that utilizes an in vivo gene delivery system to generate CAR-T cells directly in patients, potentially offering new hope by simplifying existing treatment complexities.
- Competitive Market Pressure: This acquisition positions Lilly in a market with established competitors, as Johnson & Johnson's CAR-T treatment Carvykti generated $1.89 billion in sales last year, while Gilead recently paid $7.8 billion for Arcellx and its rival drug, highlighting the intense competition in the sector.
- Strategic Significance: Lilly's executive Jacob Van Naarden noted that early clinical data is highly encouraging, representing not only a potential advancement for multiple myeloma patients but also validating Kelonia's platform concept, showcasing Lilly's ongoing investment and innovation capabilities in biopharmaceuticals.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 966.990
Low
950.00
Averages
1192
High
1500
Current: 966.990
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Roche Secures CE Mark for Alzheimer's Blood Test
- CE Mark Approval: Swiss pharmaceutical company Roche announced that its second Elecsys blood test for Alzheimer's disease has received CE mark approval, allowing it to sell in the region and further expand its market share in the neuroscience sector.
- Collaborative Development: The test was developed in partnership with U.S. company Eli Lilly, highlighting the ongoing collaboration between the two firms in the early diagnosis of Alzheimer's disease, which is expected to enhance market acceptance and clinical application of related products.
- Market Potential: With the global increase in Alzheimer's disease patients, the new testing tool will aid in early identification and intervention, thereby improving patient quality of life and alleviating the burden on healthcare systems, presenting significant social and economic implications.
- Strategic Importance: Securing CE mark not only strengthens Roche's competitive position in the Alzheimer's field but also lays the groundwork for future innovative product launches in the European market, reflecting the company's long-term commitment to the neuroscience domain.
See More
Eli Lilly Halts Obesity Awareness Campaign in India
- Regulatory Warning: The Drugs Controller General of India warned Eli Lilly that its obesity awareness campaign could violate prescription drug advertising regulations, prompting the company to pause its 'We Know Now' initiative to avoid potential legal risks, highlighting the strict and uncertain regulatory environment.
- Market Context: Lilly launched its GLP-1 treatment Mounjaro in India in March 2025 to address the rising obesity issue, with a government survey from 2019 to 2021 indicating that approximately 24% of women aged 15-49 and nearly 23% of men aged 15-54 were overweight or obese, showcasing significant market demand.
- Campaign Impact: Although Lilly's campaign aimed to enhance public understanding of obesity, the regulator's intervention forced the cessation of this scientifically-backed public health initiative, potentially harming the interests of patients and the healthcare community, reflecting the company's conflict between regulatory compliance and public health promotion.
- Industry Uncertainty: Lilly noted in its letter that the guidance from the regulator created 'significant regulatory uncertainty' and questioned whether even non-branded, physician-led initiatives would be restricted, illustrating the ambiguity and challenges faced by the industry in regulatory enforcement.
See More
UBS Sees 50% Upside for MBX Biosciences Stock
- Stock Potential: MBX Biosciences has surged over 230% in the past year, and UBS analysts project a further 50% upside with a price target of $60, reflecting strong market confidence in the company's prospects.
- Positive Clinical Data: UBS reports that MBX's GLP-1 treatment shows promising results in early proof of concept, particularly excelling in efficacy and tolerability, which are crucial for attracting both investors and patients.
- Expansive Market Outlook: The global market for type-2 diabetes and obesity treatments is expected to reach $190 billion by 2035, positioning MBX favorably in this rapidly growing sector, potentially driving further stock appreciation.
- Analyst Consensus: Among the 11 analysts covering MBX, 10 have rated it as a buy or strong buy, indicating widespread market confidence in MBX's future developments and reinforcing its competitive position in the biotech industry.
See More
Market Pullback as AI Stocks Face Pressure
- Market Pullback Reasons: On Tuesday, the Nasdaq fell 1.5% and the S&P 500 dropped about 0.6%, primarily due to rising oil prices and inflation concerns, leading to a cautious investor sentiment that negatively impacted AI-related stocks.
- Oil Price Fluctuations: U.S. WTI crude prices peaked above $102 per barrel on Tuesday, settling at $98.07, with uncertainties in the oil market exacerbating investor worries, particularly in the context of the Iran peace deal.
- Rising Rate Expectations: According to the CME FedWatch tool, the market's probability of a rate hike by year-end increased from 24% to 36%, causing unease among investors regarding future monetary policy shifts, especially impacting high P/E stocks.
- AI Stock Corrections: Following a rapid surge in AI-related stocks, the market is experiencing profit-taking, and while we believe the AI trade is not over, some profit-taking may persist in the near term, affecting data center-related stocks like Corning, GE Vernova, and Broadcom.
See More
Eli Lilly Supports Nationwide Nutritious Food Distribution Initiative
- Charitable Support Initiative: Eli Lilly collaborates with organizations like HATCH and United Way to distribute approximately 500,000 nutritious meals nationwide, addressing food inequality in communities while enhancing the company's image of social responsibility.
- Infrastructure Development: The initiative will aid in establishing cold storage infrastructure at 150 food pantries, expected to provide five million protein-rich meals annually, ensuring long-term community needs are met and enhancing the sustainability of food distribution.
- Community Engagement: Lilly's involvement in Indiana and 14 other communities promotes local food distribution efforts and enhances employee volunteer opportunities, reflecting the company's commitment to community health.
- Long-term Impact: By supporting the Pacers Foundation's Drive & Dish program, Lilly not only improves access to nutritious food but also lays the groundwork for future healthy eating choices, showcasing its leadership in public health initiatives.
See More
Eli Lilly Supports Nationwide Nutritious Food Distribution Initiative
- Charitable Support Initiative: Eli Lilly collaborates with organizations like HATCH and United Way to distribute approximately 500,000 nutritious meals across 15 communities, reflecting the company's commitment to enhancing community health and access to food.
- Infrastructure Development: The initiative will provide cold storage equipment to 150 food pantries, enabling the distribution of an estimated five million protein-rich meals annually, thereby ensuring long-term food access and enhancing the company's social responsibility image.
- Community Engagement: Lilly also supports the Pacers Foundation's expansion of the Drive & Dish program in Marion and Boone Counties, helping more families access healthy food, which demonstrates the company's proactive role in promoting community health and well-being.
- Long-term Impact: Launched in celebration of Lilly's 150th anniversary, this initiative will continue through employee volunteer efforts and ongoing food distribution activities, ensuring sustained support for communities and solidifying Lilly's leadership in social responsibility.
See More
Roche Secures CE Mark for Alzheimer's Blood Test
- CE Mark Approval: Swiss pharmaceutical company Roche announced that its second Elecsys blood test for Alzheimer's disease has received CE mark approval, allowing it to sell in the region and further expand its market share in the neuroscience sector.
- Collaborative Development: The test was developed in partnership with U.S. company Eli Lilly, highlighting the ongoing collaboration between the two firms in the early diagnosis of Alzheimer's disease, which is expected to enhance market acceptance and clinical application of related products.
- Market Potential: With the global increase in Alzheimer's disease patients, the new testing tool will aid in early identification and intervention, thereby improving patient quality of life and alleviating the burden on healthcare systems, presenting significant social and economic implications.
- Strategic Importance: Securing CE mark not only strengthens Roche's competitive position in the Alzheimer's field but also lays the groundwork for future innovative product launches in the European market, reflecting the company's long-term commitment to the neuroscience domain.
See More
Eli Lilly Halts Obesity Awareness Campaign in India
- Regulatory Warning: The Drugs Controller General of India warned Eli Lilly that its obesity awareness campaign could violate prescription drug advertising regulations, prompting the company to pause its 'We Know Now' initiative to avoid potential legal risks, highlighting the strict and uncertain regulatory environment.
- Market Context: Lilly launched its GLP-1 treatment Mounjaro in India in March 2025 to address the rising obesity issue, with a government survey from 2019 to 2021 indicating that approximately 24% of women aged 15-49 and nearly 23% of men aged 15-54 were overweight or obese, showcasing significant market demand.
- Campaign Impact: Although Lilly's campaign aimed to enhance public understanding of obesity, the regulator's intervention forced the cessation of this scientifically-backed public health initiative, potentially harming the interests of patients and the healthcare community, reflecting the company's conflict between regulatory compliance and public health promotion.
- Industry Uncertainty: Lilly noted in its letter that the guidance from the regulator created 'significant regulatory uncertainty' and questioned whether even non-branded, physician-led initiatives would be restricted, illustrating the ambiguity and challenges faced by the industry in regulatory enforcement.
See More
UBS Sees 50% Upside for MBX Biosciences Stock
- Stock Potential: MBX Biosciences has surged over 230% in the past year, and UBS analysts project a further 50% upside with a price target of $60, reflecting strong market confidence in the company's prospects.
- Positive Clinical Data: UBS reports that MBX's GLP-1 treatment shows promising results in early proof of concept, particularly excelling in efficacy and tolerability, which are crucial for attracting both investors and patients.
- Expansive Market Outlook: The global market for type-2 diabetes and obesity treatments is expected to reach $190 billion by 2035, positioning MBX favorably in this rapidly growing sector, potentially driving further stock appreciation.
- Analyst Consensus: Among the 11 analysts covering MBX, 10 have rated it as a buy or strong buy, indicating widespread market confidence in MBX's future developments and reinforcing its competitive position in the biotech industry.
See More
Market Pullback as AI Stocks Face Pressure
- Market Pullback Reasons: On Tuesday, the Nasdaq fell 1.5% and the S&P 500 dropped about 0.6%, primarily due to rising oil prices and inflation concerns, leading to a cautious investor sentiment that negatively impacted AI-related stocks.
- Oil Price Fluctuations: U.S. WTI crude prices peaked above $102 per barrel on Tuesday, settling at $98.07, with uncertainties in the oil market exacerbating investor worries, particularly in the context of the Iran peace deal.
- Rising Rate Expectations: According to the CME FedWatch tool, the market's probability of a rate hike by year-end increased from 24% to 36%, causing unease among investors regarding future monetary policy shifts, especially impacting high P/E stocks.
- AI Stock Corrections: Following a rapid surge in AI-related stocks, the market is experiencing profit-taking, and while we believe the AI trade is not over, some profit-taking may persist in the near term, affecting data center-related stocks like Corning, GE Vernova, and Broadcom.
See More
Eli Lilly Supports Nationwide Nutritious Food Distribution Initiative
- Charitable Support Initiative: Eli Lilly collaborates with organizations like HATCH and United Way to distribute approximately 500,000 nutritious meals nationwide, addressing food inequality in communities while enhancing the company's image of social responsibility.
- Infrastructure Development: The initiative will aid in establishing cold storage infrastructure at 150 food pantries, expected to provide five million protein-rich meals annually, ensuring long-term community needs are met and enhancing the sustainability of food distribution.
- Community Engagement: Lilly's involvement in Indiana and 14 other communities promotes local food distribution efforts and enhances employee volunteer opportunities, reflecting the company's commitment to community health.
- Long-term Impact: By supporting the Pacers Foundation's Drive & Dish program, Lilly not only improves access to nutritious food but also lays the groundwork for future healthy eating choices, showcasing its leadership in public health initiatives.
See More
Eli Lilly Supports Nationwide Nutritious Food Distribution Initiative
- Charitable Support Initiative: Eli Lilly collaborates with organizations like HATCH and United Way to distribute approximately 500,000 nutritious meals across 15 communities, reflecting the company's commitment to enhancing community health and access to food.
- Infrastructure Development: The initiative will provide cold storage equipment to 150 food pantries, enabling the distribution of an estimated five million protein-rich meals annually, thereby ensuring long-term food access and enhancing the company's social responsibility image.
- Community Engagement: Lilly also supports the Pacers Foundation's expansion of the Drive & Dish program in Marion and Boone Counties, helping more families access healthy food, which demonstrates the company's proactive role in promoting community health and well-being.
- Long-term Impact: Launched in celebration of Lilly's 150th anniversary, this initiative will continue through employee volunteer efforts and ongoing food distribution activities, ensuring sustained support for communities and solidifying Lilly's leadership in social responsibility.
See More
